Hematological Malignancies

Does 90 Y Ibritumomab Consolidation after first line R-Chemo Induction in Follicular Lymphoma improve outcome?  FIT study (R-chemo subgroup; n=59)  CR rate after Zevalin : 93% (controls: 71%)  PFS at 84 months: 64% Zevalin vs 23% controls (median follow-up: 71.6 months) • ECOG 1496 6-8 x chemo - CR/PR/SD randomised 16 cycles of Rituximab – similar results for PFS  Randomised ( 90 Y Ibritumomab) vs in Rituximab maintenance (ROZETTA study) no significant difference in PFS